Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment
MetadataShow full item record
Background: Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol levels, substantially increased risk of early-onset coronary heart disease (CHD) and premature mortality. If FH is untreated, it leads to a greater than 50 % risk of CHD in men by the age of 50 and at least 30 % in women by the age of 60. FH can be diagnosed through genetic screening and effectively managed through pharmacological treatment and lifestyle changes. Purpose: Familial hypercholesterolemia (FH) is a genetic health condition that increases the risk of cardiovascular disease. Although FH can be effectively managed with appropriate pharmacological and dietary interventions, FH detection rate through genetic screening remains low. The present study explored perceptions and experiences of FH patients (N = 18) involved in a genetic cascade screening programme. Methods: Face-to-face interviews were conducted to assess patients’ knowledge and understanding of FH, explore factors linked to adherence to health-protective behaviours and examine perceptions of genetic screening. Results: Thematic analysis of interviews revealed four themes: disease knowledge, severity of FH, lifestyle behavioural change and barriers to cascade screening and treatment. Participants recognised FH as a permanent, genetic condition that increased their risk of CHD and premature mortality. Many participants dismissed the seriousness of FH and the importance of lifestyle changes because they perceived it to be effectively managed through medication. Despite positive attitudes toward screening, many participants reported that relatives were reluctant to attend screening due to their relatives’ ‘fatalistic’ outlook or low motivation. Participants believed that they had insufficient authority or control to persuade family members to attend screening and welcomed greater hospital assistance for contact with relatives. Conclusions: Findings support the adoption of direct methods of recruitment to cascade screening led by medical professionals, who were perceived as having greater authority. Other implications included the need for clinicians to provide clear information, particularly to those who are asymptomatic, related to the seriousness of FH and the necessity for adherence to medication and lifestyle changes.
The final publication is available at Springer via http://doi.org/10.1007/s12529-014-9402-x
Showing items related by title, author, creator and subject.
Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatmentHardcastle, S.; Legge, E.; Laundy, C.; Egan, Sarah; French, R.; Watts, G.; Hagger, Martin (2015)Background - Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol ...
Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemiaAdemi, Z.; Watts, G.; Pang, J.; Sijbrands, E.; Van Bockxmeer, F.; O'Leary, Peter; Geelhoed, E.; Liew, D. (2014)Background: Familial hypercholesterolemia (FH) imposes significant burden of premature coronary heart disease (CHD). Objective: This study aimed to determine the cost-effectiveness of FH detection based on genetic testing, ...
Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemiaLázaro, P.; Pérez de Isla, L.; Watts, G.; Alonso, R.; Norman, Richard; Muñiz, O.; Fuentes, F.; Mata, N.; López-Miranda, J.; González-Juanatey, J.; Díaz-Díaz, J.; Blasco, A.; Mata, P. (2016)Background: Although familial hypercholesterolemia (FH) confers a high risk of coronary artery disease, most patients are undiagnosed, and little is known about the efficiency of genetic cascade screening programs at ...